PeterLabs Holdings Berhad

KLSE:PLABS Stock Report

Market Cap: RM 55.0m

PeterLabs Holdings Berhad Past Earnings Performance

Past criteria checks 0/6

PeterLabs Holdings Berhad's earnings have been declining at an average annual rate of -5.9%, while the Pharmaceuticals industry saw earnings growing at 11.6% annually. Revenues have been growing at an average rate of 15.5% per year. PeterLabs Holdings Berhad's return on equity is 4.2%, and it has net margins of 1.6%.

Key information

-5.9%

Earnings growth rate

-11.8%

EPS growth rate

Pharmaceuticals Industry Growth7.7%
Revenue growth rate15.5%
Return on equity4.2%
Net Margin1.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is PeterLabs Holdings Berhad (KLSE:PLABS) Using Too Much Debt?

Dec 20
Is PeterLabs Holdings Berhad (KLSE:PLABS) Using Too Much Debt?

PeterLabs Holdings Berhad (KLSE:PLABS) Seems To Use Debt Quite Sensibly

Nov 10
PeterLabs Holdings Berhad (KLSE:PLABS) Seems To Use Debt Quite Sensibly

Is PeterLabs Holdings Berhad (KLSE:PLABS) A Risky Investment?

Jan 28
Is PeterLabs Holdings Berhad (KLSE:PLABS) A Risky Investment?

With EPS Growth And More, PeterLabs Holdings Berhad (KLSE:PLABS) Makes An Interesting Case

Nov 10
With EPS Growth And More, PeterLabs Holdings Berhad (KLSE:PLABS) Makes An Interesting Case

Is Now The Time To Put PeterLabs Holdings Berhad (KLSE:PLABS) On Your Watchlist?

Feb 02
Is Now The Time To Put PeterLabs Holdings Berhad (KLSE:PLABS) On Your Watchlist?

Are PeterLabs Holdings Berhad's (KLSE:PLABS) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Dec 28
Are PeterLabs Holdings Berhad's (KLSE:PLABS) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Are PeterLabs Holdings Berhad's (KLSE:PLABS) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30
Are PeterLabs Holdings Berhad's (KLSE:PLABS) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Revenue & Expenses Breakdown

How PeterLabs Holdings Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KLSE:PLABS Revenue, expenses and earnings (MYR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241773170
30 Jun 241823180
31 Mar 241853180
31 Dec 231863180
30 Sep 231813190
30 Jun 231733170
31 Mar 231693170
31 Dec 221624170
30 Sep 221635160
30 Jun 221715160
31 Mar 221765170
31 Dec 211845180
30 Sep 211615160
30 Jun 211344160
31 Mar 211074140
31 Dec 20804120
30 Sep 20854120
30 Jun 20904120
31 Mar 20954130
31 Dec 19964120
30 Sep 19964120
30 Jun 19944110
31 Mar 19924110
31 Dec 18904120
30 Sep 18884120
30 Jun 18934120
31 Mar 18934120
31 Dec 17954120
30 Sep 17963120
30 Jun 17904120
31 Mar 17874120
31 Dec 16843120
30 Sep 16803110
30 Jun 16804110
31 Mar 16773100
31 Dec 15733100
30 Sep 15704100
30 Jun 1563390
31 Mar 1561390
31 Dec 1455380
30 Sep 1452280
30 Jun 1451280
31 Mar 1450280
31 Dec 1350270

Quality Earnings: PLABS has a large one-off gain of MYR1.9M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: PLABS's current net profit margins (1.6%) are lower than last year (1.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PLABS's earnings have declined by 5.9% per year over the past 5 years.

Accelerating Growth: PLABS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PLABS had negative earnings growth (-14.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-16.4%).


Return on Equity

High ROE: PLABS's Return on Equity (4.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 04:32
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PeterLabs Holdings Berhad is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yap Huey ChiangRHB Investment Bank